Halofuginone
Cat.No:IH0200 Solarbio
CAS:55837-20-2
Molecular Formula:C16H17BrClN3O3
Molecular Weight:414.68
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to off-white Solid
Qty:
Size:
{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Cell Cycle > HalofuginoneCAS:55837-20-2
Molecular Formula:C16H17BrClN3O3
Molecular Weight:414.68
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to off-white Solid
Qty:
Size:
| CAS | 55837-20-2 |
| Name | Halofuginone |
| Molecular Formula | C16H17BrClN3O3 |
| Molecular Weight | 414.68 |
| Solubility | Soluble in DMSO |
| Purity | ≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
| Delivery Time | 1-2 Days |
| EC | EINECS 1806241-263-5 |
| MDL | MFCD09834143 |
| SMILES | O=C1N(CC(C[C@@H]2NCCC[C@H]2O)=O)C=NC3=C1C=C(Cl)C(Br)=C3 |
| InChIKey | LVASCWIMLIKXLA-LSDHHAIUSA-N |
| InChI | InChI=1S/C16H17BrClN3O3/c17-11-6-13-10(5-12(11)18)16(24)21(8-20-13)7-9(22)4-14-15(23)2-1-3-19-14/h5-6,8,14-15,19,23H,1-4,7H2/t14-,15+/m0/s1 |
| PubChem CID | 400772 |
| Target Point | prolyl-tRNA synthetase |
| Passage | Cell Cycle;DNA Damage/DNA Repair |
| Background | Halofuginone is a competitive prolyl-tRNA synthetase inhibitor. Halofuginone has anti-malarial, anti-inflammatory, anti-cancer and anti-fibrosis activities. |
| Biological Activity | Halofuginone 是 Febrifugine 的一种低毒性衍生物,可从 Dichroa febrifuga 中分离出来[1]。Halofuginone 是一种 ATP 竞争性的脯氨酰-tRNA 合成酶 (prolyl-tRNA synthetase) 抑制剂,Ki 为 18.3 nM[2]。Halofuginone 通过抑制 TGF-β 活性可减轻骨关节炎[3]。 |
| Data Literature Source | [1]. Tsuchida K,et al. Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation. Free Radic Biol Med. 2017 Feb;103:236-247. [2]. Keller TL,et al. Halofuginone and other Febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol. 2012 Feb 12;8(3):311-7. [3]. Cui Z,et al. Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone. Ann Rheum Dis. 2016 Sep;75(9):1714-21. |
| Unit | Bottle |
| Specification | 5mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download